The new seriniquinone glycoside by biological transformation using the deep sea-derived bacterium Bacillus licheniformis KDM612

DOI オープンアクセス

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Seriniquinone was isolated as a melanoma-selective anti-cancer agent from a culture broth of the marine-derived bacterium <jats:italic>Serinicoccus marinus</jats:italic> CNJ927 in 2014. It targets the unique small protein, dermcidin, which affects the drug resistance of cancer cells. Due to its significant activity against cancer cells, particularly melanoma, and its unique target, seriniquinone has been developed as a new pharmacophore. However, it has the disadvantage of poor solubility in drug discovery research, which needs to be resolved. A new seriniquinone glycoside (<jats:bold>1</jats:bold>) was synthesized by the biological transformation of seriniquinone using the deep sea-derived bacterium <jats:italic>Bacillus licheniformis</jats:italic> KDM612. Compound <jats:bold>1</jats:bold> exhibited selective anti-cancer activity against melanoma, similar to seriniquinone, and was 50-fold more soluble in DMSO than seriniquinone.</jats:p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ